Memantine Versus Donepezil in Early Stages of Alzheimer's Disease

Status Completed

Clinical Trial Summary

It is well known that in the brain of the patients with Alzheimer's disease there is a glutamatergic hyperstimulation leading to neuronal death. Memantine is a low affinity antagonist of NMDA glutamate receptors. The use of this drug in the early phases of the disease could provide neuroprotective effects and delay of progression. The effects of memantine should be compared to those of donepezil, which is the most prescribed anticholinesterase drug.

Clinical Trial Description

On the basis of the excess of glutamatergic stimulation, our objective is to demonstrate whether memantine could have a neuroprotective effect in Alzheimer's disease when administered in the early stages and in comparison to donepezil. The patients would be randomized to receive one of these drugs. At baseline we would evaluate the patients from a clinical standpoint with the ADAS-cog, the neuropsychiatric Inventory and a scale of daily living activities.We also would carry out Magnetic Resonance Spectroscopy in several areas of the brain (medial temporal lobe, prefrontal region, cingulate gyrus and occipital lobe) so as to measure the concentration of N-acetyl-aspartate which is a marker of neuronal density.Then we treat the patients with either memantine or denepezil and after 6 months we would repeat the same procedures as we did at baseline. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00505167
Study type	Interventional
Source	Hospital Miguel Servet
Contact
Status	Completed
Phase	Phase 4
Start date	July 2007
Completion date	December 2008

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT00154635` - Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer’s Disease	Phase 2
Completed	`NCT00208819` - A Comparison of Two Standard Therapies in the Management of Dementia With Agitation	Phase 4
Completed	`NCT00997425` - Home Evaluation of Exit Barriers in Wandering	N/A
Terminated	`NCT02322021` - Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease	Phase 2
Completed	`NCT03119259` - Technology Intervention to Support Caregiving for Alzheimer's Disease (I-CARE)	N/A
Completed	`NCT00099242` - Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease	Phase 3
Completed	`NCT03721705` - Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type	Phase 3
Not yet recruiting	`NCT05113732` - Association of Cognition With Functional Mobility in People With Alzheimer's Disease
Active, not recruiting	`NCT03661034` - Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)	N/A
Completed	`NCT03160027` - Photobiomodulation for Improving Brain Function in Dementia (PBM Dementia)	N/A
Completed	`NCT03475316` - Movement Intervention for Memory Enhancement	N/A
Completed	`NCT02727699` - A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)	Phase 2
Completed	`NCT00259454` - Project COPE:Managing Dementia at Home	Phase 3
Completed	`NCT03246269` - Normative Values for the German Version of the Montreal Cognitive Assessment (MoCA)
Recruiting	`NCT03890861` - Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)"	N/A
Completed	`NCT03991195` - Intervention of Intestinal Microorganism in Mild Cognitive Impairment	N/A
Completed	`NCT00515333` - TRx0014 in Patients With Mild or Moderate Alzheimer's Disease	Phase 2
Completed	`NCT01438060` - Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type	Phase 3
Completed	`NCT03622814` - Partners at Meals - Respite Care and Home (PAM)	N/A
Recruiting	`NCT03672266` - Studies of Brain and Body Interaction